$54.13
0.090.17%
Pre-Market: 8:03 AM EDT
15 minutes delayed
Comments
Loading...
Halozyme Therapeutics
HALONASDAQ
Halozyme Therapeutics (NASDAQ:HALO) Stock, Guidance And Forecast
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 06/06/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.65 | $4.05 | $3.73 | $935.00M | $1.01B | $947.33M | Get Alert |
| 05/07/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.55 | $3.90 | $3.68 | $915.00M | $985.00M | $951.47M | Get Alert |
| 02/20/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.55 | $3.90 | $3.51 | $915.00M | $985.00M | $961.09M | Get Alert |
| 01/17/2024 | HALO | Halozyme Therapeutics | FY | 2023 | $2.77 | $2.80 | $2.74 | $827.00M | $832.00M | $835.69M | Get Alert |
| 11/06/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.70 | $2.80 | $2.65 | $825.00M | $845.00M | $835.91M | Get Alert |
| 08/08/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.65 | $2.75 | $2.61 | $825.00M | $845.00M | $823.06M | Get Alert |
| 05/09/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.57 | $815.00M | $845.00M | $833.00M | Get Alert |
| 03/15/2023 | HALO | Halozyme Therapeutics | FY | 2023 | — | — | — | $815.00M | $845.00M | $829.01M | Get Alert |
| 02/21/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.78 | $815.00M | $845.00M | $868.12M | Get Alert |
| 01/10/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.90 | $815.00M | $845.00M | $892.47M | Get Alert |
| 11/08/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.10 | $2.25 | $2.04 | $655.00M | $685.00M | $661.33M | Get Alert |
| 08/09/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.10 | $2.25 | $2.23 | $655.00M | $685.00M | $610.87M | Get Alert |
| 05/10/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.23 | $530.00M | $560.00M | $566.18M | Get Alert |
| 04/13/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.18 | $530.00M | $560.00M | $553.27M | Get Alert |
| 02/22/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.18 | $530.00M | $560.00M | $554.20M | Get Alert |
| 01/10/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.68 | $530.00M | $560.00M | $569.39M | Get Alert |
| 11/02/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.90 | $2.00 | — | $430.00M | $445.00M | — | Get Alert |
| 08/09/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.85 | $2.00 | $1.41 | $425.00M | $445.00M | $404.56M | Get Alert |
| 05/10/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.55 | $1.70 | $1.55 | $375.00M | $395.00M | $389.96M | Get Alert |
| 02/23/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.40 | $1.55 | $1.70 | $375.00M | $395.00M | $400.15M | Get Alert |
| 01/13/2021 | HALO | Halozyme Therapeutics | FY | 2020 | $0.90 | $0.95 | $0.93 | $265.00M | $275.00M | $265.30M | Get Alert |
| 01/11/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.40 | $1.55 | $1.79 | $375.00M | $395.00M | $403.71M | Get Alert |
| 11/23/2020 | HALO | Halozyme Therapeutics | FY | 2020 | $0.90 | $0.95 | $0.86 | $265.00M | $275.00M | $255.12M | Get Alert |
| 11/02/2020 | HALO | Halozyme Therapeutics | FY | 2020 | $0.80 | $0.85 | $0.69 | $250.00M | $260.00M | $235.94M | Get Alert |
| 02/24/2020 | HALO | Halozyme Therapeutics | FY | 2020 | $0.60 | $0.75 | $0.58 | $230.00M | $245.00M | $220.68M | Get Alert |
| 01/14/2020 | HALO | Halozyme Therapeutics | FY | 2020 | $0.60 | $0.75 | $0.56 | $230.00M | $245.00M | $227.01M | Get Alert |
| 01/14/2020 | HALO | Halozyme Therapeutics | FY | 2019 | — | — | — | $195.00M | $195.00M | $203.13M | Get Alert |
| 11/12/2019 | HALO | Halozyme Therapeutics | FY | 2019 | — | — | — | $195.00M | $205.00M | $204.86M | Get Alert |
FAQ
What is the most recent guidance for Halozyme Therapeutics (HALO)?
The last reported Earnings numbers were from June 6, 2024 for the full year 2024 and was for an earnings per share guidance in the range of $3.65 and $4.05 versus the estimated EPS of $3.73.
Browse guidance and forecast on all stocks.